Immune to Cancer: The CRI Blog
-
Bladder Cancer Awareness Month: 2022 Immunotherapy Research Updates
This Bladder Cancer Awareness Month, discover new research, new treatments, and progress for a future immune to…
-
Bladder Cancer Awareness Month: 2021 Immunotherapy Research Updates
This May for Bladder Cancer Awareness Month, we look at new research, new treatments, and how we’re…
-
Dr. Terence Friedlander Answers Questions on Bladder Cancer and Immunotherapy from the CRI Virtual Immunotherapy Patient Summit
Terence Friedlander, MD, answers questions about immunotherapy for bladder cancer from the 2020 CRI Virtual Immunotherapy Patient…
-
Bladder Cancer Awareness Month: 2020 Immunotherapy Research Update
A changing treatment landscape, new scientific research, and how we’re working toward a future immune to bladder…
-
How Immunotherapy Is Transforming Bladder Cancer Treatment
Arjun V. Balar, MD, discusses checkpoint immunotherapy, new FDA approvals, promising new therapies, and clinical trials for…
-
Shirley Dumont’s Immunotherapy Story
Bladder Cancer | Diagnosed 2008 My doctor calls me the ‘bionic woman.’ This is all through immunotherapy. Shirley’s… -
Curtis Garbett’s Immunotherapy Story
Bladder Cancer | Diagnosed 2015 Advancing cancer research and visioning a future immune to bladder cancer Curtis’s Story… -
Durvalumab Becomes Newest Immunotherapy Approved for Advanced Bladder Cancer
Durvalumab marks AstraZeneca’s first immunotherapy approval
-
Atezolizumab (Tecentriq™) Receives FDA Approval for Bladder Cancer
It becomes the first FDA-approved checkpoint blockade immunotherapy for bladder cancer.